Antimicrobial Therapy in Intensive Care Unit
This reprint is an excellent collection of articles that deal with difficult-to-treat infections in the ICU environment. Multiresistant bacteria and fungi create severe treatment problems to the physician charged with their care. We hope that this book will help everyday dilemmas and add useful info...
| Format: | eBook |
|---|---|
| Language: | English |
| Published: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2023
|
| Subjects: | |
| Online Access: | Open Access: DOAB: description of the publication Open Access: DOAB, download the publication |
| LEADER | 04830namaa2201477uu 4500 | ||
|---|---|---|---|
| 001 | doab98906 | ||
| 003 | oapen | ||
| 005 | 20230405 | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 230405s2023 xx |||||o ||| 0|eng d | ||
| 020 | |a 9783036567686 | ||
| 020 | |a 9783036567693 | ||
| 020 | |a books978-3-0365-6768-6 | ||
| 024 | 7 | |a 10.3390/books978-3-0365-6768-6 |2 doi | |
| 040 | |a oapen |c oapen | ||
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a M |2 bicssc | |
| 720 | 1 | |a Paramythiotou, Elizabeth |4 edt | |
| 720 | 1 | |a Andremont, Antoine |4 edt | |
| 720 | 1 | |a Andremont, Antoine |4 oth | |
| 720 | 1 | |a Paramythiotou, Elizabeth |4 oth | |
| 720 | 1 | |a Routsi, Christina |4 edt | |
| 720 | 1 | |a Routsi, Christina |4 oth | |
| 245 | 0 | 0 | |a Antimicrobial Therapy in Intensive Care Unit |
| 260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2023 | ||
| 300 | |a 1 online resource (260 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |f Unrestricted online access |2 star | |
| 520 | |a This reprint is an excellent collection of articles that deal with difficult-to-treat infections in the ICU environment. Multiresistant bacteria and fungi create severe treatment problems to the physician charged with their care. We hope that this book will help everyday dilemmas and add useful information on difficult topics. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |u https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Medicine |2 bicssc | |
| 653 | |a Acinetobacter | ||
| 653 | |a Acinetobacter baumannii | ||
| 653 | |a antibiotic choices | ||
| 653 | |a antibiotic optimisation | ||
| 653 | |a antibiotic pressure | ||
| 653 | |a antibiotic resistance | ||
| 653 | |a antibiotic stewardship (AMS) | ||
| 653 | |a antibiotics | ||
| 653 | |a antibiotics utilization | ||
| 653 | |a antimicrobial agents | ||
| 653 | |a antimicrobial combinations | ||
| 653 | |a antimicrobial stewardship | ||
| 653 | |a APACHE II score | ||
| 653 | |a aspiration pneumonia | ||
| 653 | |a bacteraemia | ||
| 653 | |a bacteremia | ||
| 653 | |a beta-lactam antibiotics | ||
| 653 | |a biomarker | ||
| 653 | |a blood stream infection | ||
| 653 | |a bloodstream infection | ||
| 653 | |a broth microdilution | ||
| 653 | |a C-reactive protein | ||
| 653 | |a Candida species | ||
| 653 | |a candidemia | ||
| 653 | |a carbapenem-resistant A. baumannii (CRAb) | ||
| 653 | |a carbapenems | ||
| 653 | |a cefiderocol | ||
| 653 | |a clinical pharmacy services | ||
| 653 | |a colistin | ||
| 653 | |a colistin-resistant | ||
| 653 | |a colonization | ||
| 653 | |a COVID-19 | ||
| 653 | |a critical illness | ||
| 653 | |a critically ill | ||
| 653 | |a de-escalation | ||
| 653 | |a defined daily dose | ||
| 653 | |a double carbapenem | ||
| 653 | |a dysbiosis | ||
| 653 | |a ECMO | ||
| 653 | |a empiric | ||
| 653 | |a empirical | ||
| 653 | |a epidemiology | ||
| 653 | |a eravacycline | ||
| 653 | |a extracorporeal membrane oxygenation | ||
| 653 | |a fluconazole resistance | ||
| 653 | |a Gram-negative | ||
| 653 | |a guided antimicrobial therapy | ||
| 653 | |a HAP | ||
| 653 | |a hospital-acquired pneumonia (HAP) | ||
| 653 | |a ICU | ||
| 653 | |a incidence | ||
| 653 | |a infection | ||
| 653 | |a infection control | ||
| 653 | |a intensive care | ||
| 653 | |a intensive care unit | ||
| 653 | |a Klebsiella pneumoniae | ||
| 653 | |a mechanical ventilation | ||
| 653 | |a microbiome | ||
| 653 | |a Monte Carlo simulation | ||
| 653 | |a mortality | ||
| 653 | |a multidrug-resistance (MDR) | ||
| 653 | |a n/a | ||
| 653 | |a newer β-lactam-β-lactamase inhibitors | ||
| 653 | |a non-albicans Candida species | ||
| 653 | |a non-fermentative Gram-negative bacilli (GNB) | ||
| 653 | |a pandrug-resistant | ||
| 653 | |a pharmacodynamics | ||
| 653 | |a pharmacokinetics | ||
| 653 | |a pneumonia resolution | ||
| 653 | |a polymicrobial | ||
| 653 | |a presepsin | ||
| 653 | |a probabilistic antibiotics | ||
| 653 | |a probiotics | ||
| 653 | |a procalcitonin | ||
| 653 | |a Pseudomonas aeruginosa | ||
| 653 | |a renal replacement therapy | ||
| 653 | |a risk factors | ||
| 653 | |a salvage treatment | ||
| 653 | |a SARS-CoV-2 infection | ||
| 653 | |a sepsis | ||
| 653 | |a septic shock | ||
| 653 | |a SOFA score | ||
| 653 | |a source control | ||
| 653 | |a synergy | ||
| 653 | |a VAP | ||
| 653 | |a ventilator-associated pneumonia | ||
| 653 | |a ventilator-associated pneumonia (VAP) | ||
| 793 | 0 | |a DOAB Library. | |
| 856 | 4 | 0 | |u https://directory.doabooks.org/handle/20.500.12854/98906 |7 0 |z Open Access: DOAB: description of the publication |
| 856 | 4 | 0 | |u https://mdpi.com/books/pdfview/book/6959 |7 0 |z Open Access: DOAB, download the publication |